Prognostic significance of ypN status after neoadjuvant chemoimmunotherapy in resectable NSCLC: a systematic review and meta-analysis

1

Neoadjuvant chemoimmunotherapy is crucial for treating resectable non-small cell lung cancer (NSCLC), yet postoperative relapse remains common.
2

Unfavorable post-treatment nodal status (ypN+) is significantly associated with poorer overall survival and disease-free survival in resectable NSCLC.
3

The systematic review included two studies, indicating that the prognostic value of ypN status should be interpreted cautiously pending further validation.
4

Pathological assessment post-neoadjuvant therapy is essential for risk stratification, as it informs postoperative decision-making regarding treatment intensity.
5

Integration of nodal status and primary tumor response may enhance prognostic stratification compared to using either factor alone in NSCLC.

1